Sanofi Team Simulates Active Ingredients Before Clinical Trials

The pharmaceutical company uses digital twins to predict the behavior of potential new medicines.

Sanofi, a French multinational pharmaceutical company, is leveraging digital twins to streamline its research and development process. The company's team uses simulations to predict the behavior of active ingredients before conducting clinical trials. This approach enables Sanofi to identify potential issues early on and optimize its development pipeline.

The use of digital twins in pharmaceutical research is becoming increasingly common, allowing companies to reduce costs and accelerate the discovery of new treatments. Sanofi's adoption of this technology is a significant step forward in the industry.

By simulating the behavior of active ingredients, Sanofi's team can gain valuable insights into their potential efficacy and safety. This information can inform the design of clinical trials and ultimately improve the development process.